Analysis of regulatory guidance on antidrug antibody testing for therapeutic protein products
Therapeutic proteins have the potential to induce unwanted immune responses. The potential impact of immunogenicity on pharmacokinetics, pharmacodynamics, safety and efficacy are well established. Here, we analyze key aspects of current US FDA and EMA guidelines on the development and validation of antidrug antibody assays. Although FDA and EMA guidance documents are in harmony on most points, EMA allows greater leeway for scientific judgement, while FDA recommends specific approaches that may not be appropriate in some situations. Many white papers suggest approaches different from the guidance documents, however, these can conflict with each other and are themselves only scientifically valid in certain situations. Here, we indicate when alternatives to guidance may be needed and what those approaches might be.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Bioanalysis - 11(2019), 24 vom: 25. Dez., Seite 2283-2296 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bano, Nazneen [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.04.2020 Date Revised 21.04.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.4155/bio-2019-0241 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM304465178 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM304465178 | ||
| 003 | DE-627 | ||
| 005 | 20231225115038.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/bio-2019-0241 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1014.xml |
| 035 | |a (DE-627)NLM304465178 | ||
| 035 | |a (NLM)31845602 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bano, Nazneen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Analysis of regulatory guidance on antidrug antibody testing for therapeutic protein products |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.04.2020 | ||
| 500 | |a Date Revised 21.04.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Therapeutic proteins have the potential to induce unwanted immune responses. The potential impact of immunogenicity on pharmacokinetics, pharmacodynamics, safety and efficacy are well established. Here, we analyze key aspects of current US FDA and EMA guidelines on the development and validation of antidrug antibody assays. Although FDA and EMA guidance documents are in harmony on most points, EMA allows greater leeway for scientific judgement, while FDA recommends specific approaches that may not be appropriate in some situations. Many white papers suggest approaches different from the guidance documents, however, these can conflict with each other and are themselves only scientifically valid in certain situations. Here, we indicate when alternatives to guidance may be needed and what those approaches might be | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a European Medicines Agency | |
| 650 | 4 | |a Food and Drug Administration Guidelines | |
| 650 | 4 | |a antidrug antibody | |
| 650 | 4 | |a drug tolerance | |
| 650 | 4 | |a immunogenicity | |
| 650 | 4 | |a positive control | |
| 650 | 4 | |a pre-existing antibody | |
| 650 | 4 | |a sensitivity | |
| 650 | 4 | |a therapeutic proteins | |
| 650 | 7 | |a Antibodies |2 NLM | |
| 650 | 7 | |a Proteins |2 NLM | |
| 700 | 1 | |a McKelvey, Troy |e verfasserin |4 aut | |
| 700 | 1 | |a Spear, Nathan |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Tong-Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Shankar, Gopi |e verfasserin |4 aut | |
| 700 | 1 | |a Schantz, Allen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioanalysis |d 2009 |g 11(2019), 24 vom: 25. Dez., Seite 2283-2296 |w (DE-627)NLM196969840 |x 1757-6199 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2019 |g number:24 |g day:25 |g month:12 |g pages:2283-2296 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/bio-2019-0241 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2019 |e 24 |b 25 |c 12 |h 2283-2296 | ||